Monday, 20 May 2019

Agios receives nod for ivosidenib

23 July 2018 | News

Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.

Singapore – The FDA approves Agios Pharmaceuticals' TIBSOVO (ivosidenib) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.

Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls